Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
about
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic StrategiesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyEffect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialHematopoietic stem cell transplantation for MDS.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasAdministration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effectsNonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Advances in graft-versus-host disease biology and therapy.Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesPregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)The role of the marrow microenvironment in hematopoietic stem cell transplantation.Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantationPrognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationTransplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsImpact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.A disease risk index for patients undergoing allogeneic stem cell transplantation.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsReview of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and MThymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms.Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisThe evolution of hematopoietic SCT in myelodysplastic syndrome.Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity.Reduced-intensity conditioning and umbilical cord blood transplantation in adults.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
P2860
Q26751959-EF51BF1B-52C0-4FD7-91FE-44F4E383C3FFQ27010653-B8DB88BF-9107-4796-9E80-A6B3919342A6Q30408294-72681EEB-58C7-4517-9C5D-6062ED0DAE22Q30543777-C8B93061-5004-483D-84DE-81B1B1A68427Q33767314-945E1B60-F2CC-4446-9173-10E28A6FB7FDQ33850163-9C6B89C2-9968-49D9-92D9-2E163289F74EQ33905411-F8F565AC-9E3F-4274-93CF-45900C44ACEEQ33990856-E03E1BC6-0CF0-41BE-B6B2-E7C6230CCCC1Q34013826-D9194F2E-FDE5-42C5-952C-D78B87A3534DQ34031916-0714C09F-48D5-4525-917E-F86F02688097Q34049208-7F10AF99-52E6-4721-99C2-92C24E0541D9Q34360641-BEBBE327-815C-4CA5-A414-D459FE1883F1Q34463645-56F8EDF1-BF6D-408B-A857-420F2F85E16DQ34474785-DDE9B1F3-52A1-430E-836D-AC82643EFA84Q34485594-49359245-EA89-4BA7-85E0-17B9B26DB585Q34505185-D6F414C1-6983-455B-A1DB-7AB6CF129D34Q35100141-67FC07CF-543A-4EDD-8F32-D3F34EBAC05BQ35317371-3497E36A-8744-4D1B-9B44-6D4BA1C80F6AQ35641272-ED915CE1-68EC-4561-88AA-FB54AAF42CBAQ35687151-7CD488F9-6495-4D71-A802-FC4E39225DE7Q35828727-C8286D69-CEDD-4F94-B8FD-A8ADA86233FAQ35838113-9C4B728D-8F1F-4556-80CD-B87DB5DFED71Q35958215-8FB9801D-873D-466C-984A-851251983BFEQ36141944-E468C9D1-3DE6-4663-AD61-73B843DD699FQ36431041-80EA471D-E63A-4368-91C4-E464DC764CFCQ36530726-13E24DE5-E6B2-4FEC-A995-3B514C6634E7Q36742108-D2BABBBF-D196-40C6-BFE2-FE1B53F62202Q36920394-E2D1D31C-B2ED-495D-877F-11C5B67E7A02Q37104254-EF4EB89A-B744-404A-BBFF-39B0CCD8FEF9Q37159533-0C68DB75-74A9-41EE-A698-9160C8F84649Q37205584-E366CAF4-D0D3-4E5F-996C-FBB4E1C33548Q37247581-C4217E25-B2CC-4577-B8AF-736F49B1FE8DQ37286248-67D15010-5759-4E09-9169-146576DC4C4FQ37301516-C6DA3880-4A96-4BF7-909F-6F19CE40E601Q37404489-9A9BAFEC-AD4D-4AFD-ABEC-CE599824B154Q37445265-00060DDC-0713-4546-A1B4-EA63DA83D616Q37486793-954327D1-DBF2-4405-A58B-A6C28C94838EQ37539087-8F257598-8722-4C7F-AAF9-B613D05F8216Q37607984-21BCD3FE-7045-4301-98D3-1A49F39E15B0Q37718826-3311F7DD-75DA-45D2-9D3F-F27BA82E8806
P2860
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@ast
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@en
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@nl
type
label
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@ast
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@en
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@nl
prefLabel
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@ast
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@en
Impact of conditioning regimen ...... and myelodysplastic syndrome.
@nl
P2093
P1476
Impact of conditioning regimen ...... a and myelodysplastic syndrome
@en
P2093
Corey Cutler
Daniel J DeAngelo
Edwin P Alyea
Haesook T Kim
Joseph H Antin
Richard Stone
Robert J Soiffer
Vincent Ho
P304
P356
10.1016/J.BBMT.2006.06.003
P50
P577
2006-10-01T00:00:00Z